Abstract
Summary
The global market for CD38 Monoclonal Antibody Drugs was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for CD38 Monoclonal Antibody Drugs, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of CD38 Monoclonal Antibody Drugs by region & country, by Type, and by Application.
The CD38 Monoclonal Antibody Drugs market size, estimations, and forecasts are provided in terms of sales volume (KG) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding CD38 Monoclonal Antibody Drugs.
Market Segmentation
By Company
Johnson
Sanofi
Takeda Pharmaceutical Company
CASI Pharmaceutical Company
Mab Biopharma
Segment by Type:
Daretuzumab
Isartuximab
Engineered Toxin Body
Segment by Application
Multiple Myeloma
Diffuse Large B Cell Lymphoma
Other
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of CD38 Monoclonal Antibody Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of CD38 Monoclonal Antibody Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of CD38 Monoclonal Antibody Drugs in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for CD38 Monoclonal Antibody Drugs, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of CD38 Monoclonal Antibody Drugs by region & country, by Type, and by Application.
The CD38 Monoclonal Antibody Drugs market size, estimations, and forecasts are provided in terms of sales volume (KG) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding CD38 Monoclonal Antibody Drugs.
Market Segmentation
By Company
Johnson
Sanofi
Takeda Pharmaceutical Company
CASI Pharmaceutical Company
Mab Biopharma
Segment by Type:
Daretuzumab
Isartuximab
Engineered Toxin Body
Segment by Application
Multiple Myeloma
Diffuse Large B Cell Lymphoma
Other
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of CD38 Monoclonal Antibody Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of CD38 Monoclonal Antibody Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of CD38 Monoclonal Antibody Drugs in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Table of Contents
1 Market Overview
1.1 CD38 Monoclonal Antibody Drugs Product Introduction
1.2 Global CD38 Monoclonal Antibody Drugs Market Size Forecast
1.2.1 Global CD38 Monoclonal Antibody Drugs Sales Value (2019-2030)
1.2.2 Global CD38 Monoclonal Antibody Drugs Sales Volume (2019-2030)
1.2.3 Global CD38 Monoclonal Antibody Drugs Sales Price (2019-2030)
1.3 CD38 Monoclonal Antibody Drugs Market Trends & Drivers
1.3.1 CD38 Monoclonal Antibody Drugs Industry Trends
1.3.2 CD38 Monoclonal Antibody Drugs Market Drivers & Opportunity
1.3.3 CD38 Monoclonal Antibody Drugs Market Challenges
1.3.4 CD38 Monoclonal Antibody Drugs Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global CD38 Monoclonal Antibody Drugs Players Revenue Ranking (2023)
2.2 Global CD38 Monoclonal Antibody Drugs Revenue by Company (2019-2024)
2.3 Global CD38 Monoclonal Antibody Drugs Players Sales Volume Ranking (2023)
2.4 Global CD38 Monoclonal Antibody Drugs Sales Volume by Company Players (2019-2024)
2.5 Global CD38 Monoclonal Antibody Drugs Average Price by Company (2019-2024)
2.6 Key Manufacturers CD38 Monoclonal Antibody Drugs Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers CD38 Monoclonal Antibody Drugs Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of CD38 Monoclonal Antibody Drugs
2.9 CD38 Monoclonal Antibody Drugs Market Competitive Analysis
2.9.1 CD38 Monoclonal Antibody Drugs Market Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by CD38 Monoclonal Antibody Drugs Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in CD38 Monoclonal Antibody Drugs as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Daretuzumab
3.1.2 Isartuximab
3.1.3 Engineered Toxin Body
3.2 Global CD38 Monoclonal Antibody Drugs Sales Value by Type
3.2.1 Global CD38 Monoclonal Antibody Drugs Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global CD38 Monoclonal Antibody Drugs Sales Value, by Type (2019-2030)
3.2.3 Global CD38 Monoclonal Antibody Drugs Sales Value, by Type (%) (2019-2030)
3.3 Global CD38 Monoclonal Antibody Drugs Sales Volume by Type
3.3.1 Global CD38 Monoclonal Antibody Drugs Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global CD38 Monoclonal Antibody Drugs Sales Volume, by Type (2019-2030)
3.3.3 Global CD38 Monoclonal Antibody Drugs Sales Volume, by Type (%) (2019-2030)
3.4 Global CD38 Monoclonal Antibody Drugs Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Multiple Myeloma
4.1.2 Diffuse Large B Cell Lymphoma
4.1.3 Other
4.2 Global CD38 Monoclonal Antibody Drugs Sales Value by Application
4.2.1 Global CD38 Monoclonal Antibody Drugs Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global CD38 Monoclonal Antibody Drugs Sales Value, by Application (2019-2030)
4.2.3 Global CD38 Monoclonal Antibody Drugs Sales Value, by Application (%) (2019-2030)
4.3 Global CD38 Monoclonal Antibody Drugs Sales Volume by Application
4.3.1 Global CD38 Monoclonal Antibody Drugs Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global CD38 Monoclonal Antibody Drugs Sales Volume, by Application (2019-2030)
4.3.3 Global CD38 Monoclonal Antibody Drugs Sales Volume, by Application (%) (2019-2030)
4.4 Global CD38 Monoclonal Antibody Drugs Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global CD38 Monoclonal Antibody Drugs Sales Value by Region
5.1.1 Global CD38 Monoclonal Antibody Drugs Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global CD38 Monoclonal Antibody Drugs Sales Value by Region (2019-2024)
5.1.3 Global CD38 Monoclonal Antibody Drugs Sales Value by Region (2025-2030)
5.1.4 Global CD38 Monoclonal Antibody Drugs Sales Value by Region (%), (2019-2030)
5.2 Global CD38 Monoclonal Antibody Drugs Sales Volume by Region
5.2.1 Global CD38 Monoclonal Antibody Drugs Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global CD38 Monoclonal Antibody Drugs Sales Volume by Region (2019-2024)
5.2.3 Global CD38 Monoclonal Antibody Drugs Sales Volume by Region (2025-2030)
5.2.4 Global CD38 Monoclonal Antibody Drugs Sales Volume by Region (%), (2019-2030)
5.3 Global CD38 Monoclonal Antibody Drugs Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America CD38 Monoclonal Antibody Drugs Sales Value, 2019-2030
5.4.2 North America CD38 Monoclonal Antibody Drugs Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe CD38 Monoclonal Antibody Drugs Sales Value, 2019-2030
5.5.2 Europe CD38 Monoclonal Antibody Drugs Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific CD38 Monoclonal Antibody Drugs Sales Value, 2019-2030
5.6.2 Asia Pacific CD38 Monoclonal Antibody Drugs Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America CD38 Monoclonal Antibody Drugs Sales Value, 2019-2030
5.7.2 South America CD38 Monoclonal Antibody Drugs Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa CD38 Monoclonal Antibody Drugs Sales Value, 2019-2030
5.8.2 Middle East & Africa CD38 Monoclonal Antibody Drugs Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions CD38 Monoclonal Antibody Drugs Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions CD38 Monoclonal Antibody Drugs Sales Value
6.2.1 Key Countries/Regions CD38 Monoclonal Antibody Drugs Sales Value, 2019-2030
6.2.2 Key Countries/Regions CD38 Monoclonal Antibody Drugs Sales Volume, 2019-2030
6.3 United States
6.3.1 United States CD38 Monoclonal Antibody Drugs Sales Value, 2019-2030
6.3.2 United States CD38 Monoclonal Antibody Drugs Sales Value by Type (%), 2023 VS 2030
6.3.3 United States CD38 Monoclonal Antibody Drugs Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe CD38 Monoclonal Antibody Drugs Sales Value, 2019-2030
6.4.2 Europe CD38 Monoclonal Antibody Drugs Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe CD38 Monoclonal Antibody Drugs Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China CD38 Monoclonal Antibody Drugs Sales Value, 2019-2030
6.5.2 China CD38 Monoclonal Antibody Drugs Sales Value by Type (%), 2023 VS 2030
6.5.3 China CD38 Monoclonal Antibody Drugs Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan CD38 Monoclonal Antibody Drugs Sales Value, 2019-2030
6.6.2 Japan CD38 Monoclonal Antibody Drugs Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan CD38 Monoclonal Antibody Drugs Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea CD38 Monoclonal Antibody Drugs Sales Value, 2019-2030
6.7.2 South Korea CD38 Monoclonal Antibody Drugs Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea CD38 Monoclonal Antibody Drugs Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia CD38 Monoclonal Antibody Drugs Sales Value, 2019-2030
6.8.2 Southeast Asia CD38 Monoclonal Antibody Drugs Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia CD38 Monoclonal Antibody Drugs Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India CD38 Monoclonal Antibody Drugs Sales Value, 2019-2030
6.9.2 India CD38 Monoclonal Antibody Drugs Sales Value by Type (%), 2023 VS 2030
6.9.3 India CD38 Monoclonal Antibody Drugs Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Johnson
7.1.1 Johnson Company Information
7.1.2 Johnson Introduction and Business Overview
7.1.3 Johnson CD38 Monoclonal Antibody Drugs Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Johnson CD38 Monoclonal Antibody Drugs Product Offerings
7.1.5 Johnson Recent Development
7.2 Sanofi
7.2.1 Sanofi Company Information
7.2.2 Sanofi Introduction and Business Overview
7.2.3 Sanofi CD38 Monoclonal Antibody Drugs Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Sanofi CD38 Monoclonal Antibody Drugs Product Offerings
7.2.5 Sanofi Recent Development
7.3 Takeda Pharmaceutical Company
7.3.1 Takeda Pharmaceutical Company Company Information
7.3.2 Takeda Pharmaceutical Company Introduction and Business Overview
7.3.3 Takeda Pharmaceutical Company CD38 Monoclonal Antibody Drugs Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Takeda Pharmaceutical Company CD38 Monoclonal Antibody Drugs Product Offerings
7.3.5 Takeda Pharmaceutical Company Recent Development
7.4 CASI Pharmaceutical Company
7.4.1 CASI Pharmaceutical Company Company Information
7.4.2 CASI Pharmaceutical Company Introduction and Business Overview
7.4.3 CASI Pharmaceutical Company CD38 Monoclonal Antibody Drugs Sales, Revenue and Gross Margin (2019-2024)
7.4.4 CASI Pharmaceutical Company CD38 Monoclonal Antibody Drugs Product Offerings
7.4.5 CASI Pharmaceutical Company Recent Development
7.5 Mab Biopharma
7.5.1 Mab Biopharma Company Information
7.5.2 Mab Biopharma Introduction and Business Overview
7.5.3 Mab Biopharma CD38 Monoclonal Antibody Drugs Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Mab Biopharma CD38 Monoclonal Antibody Drugs Product Offerings
7.5.5 Mab Biopharma Recent Development
8 Industry Chain Analysis
8.1 CD38 Monoclonal Antibody Drugs Industrial Chain
8.2 CD38 Monoclonal Antibody Drugs Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 CD38 Monoclonal Antibody Drugs Sales Model
8.5.2 Sales Channel
8.5.3 CD38 Monoclonal Antibody Drugs Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer